Martha Sajatovic, MD
Department of Psychiatry and Department of Neurology, Case Western Reserve University School of Medicine, Cleveland, Ohio
Academic Highlights
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
June 13, 2025
A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
Original Research
Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia
September 25, 2023
Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...
Original Research
Long-Acting Injectable Antipsychotic Plus Customized Adherence Enhancement
September 16, 2021
Medication adherence is often difficult in bipolar patients. This trial combined a behavioral customized adherence enhancement approach with long-acting injectable antipsychotics and assessed effects on adherence, symptoms, and functional...
Consensus Statement
Screening, Diagnosis, and Treatment of Tardive Dyskinesia
January 28, 2020
Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
Original Research
Customized Adherence Enhancement for Bipolar Disorder
September 25, 2018
Treatment nonadherence is bipolar disorder ranges from 20% to 60%. Read this article to learn how customized adherence enhancement (CAE)—a brief, bipolar disorder-specific approach that targets individual adherence barriers—compared...
